Last updated: 11/07/2018 14:04:58
A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression
Trial description: A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Antidepressant efficacy of controlled release paroxetine hcl. Golden, R N, Nemeroff, C B, Pitts, C D, and Dube, E M 41st Annual Meeting of the American College of Neuropsychopharmacology 12/8/2002 San Juan; Puerto Rico
Efficacy and tolerability of controlled-release paroxetine. Golden, R. N. Psychopharmacol Bull 2003; 37 Suppl 1(176-86)
Golden, R.N.; Nemeroff, C.B.; Mcsorley, P.; Pits, CD; Dube, E.M. (2002), Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J. Clin Psychiatry 2002 Jul;63(7):577-584
Tolerability and pharmacokinetics of controlled - and immediate release paroxetine in the treatment of major depression and anxiety disorders. Golden, R. N., Perera, P., Lipschitz, A., and Carpenter, D. 42nd Annual Meeting of the American College of Neuropsychopharmacology 12/7/2003 Puerto Rico
Tolerability and pharmacokinetics of controlled- and immediate-release ssris. Golden, Robert N. M. D., Perera, Philip M. D., Holdsworth, Simon B. S. C., and Zussman, Barry B. S. C. 156th Annual Meeting of the American Psychiatric Association 5/17/2003 San Francisco, CA; USA
Medical condition
Depressive Disorder, Major
Product
paroxetine
Collaborators
Not applicable
Study date(s)
September 1996 to June 1997
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1997-13-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website